Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer

Seminars in Radiation Oncology

Volumn 9, Issue 2 SUPPL. 1, 1999, Pages 70-76

  Vokes, E E ^a   Haraf, D J ^a   Brockstein, B E ^a   Weichselbaum, R R ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; PACLITAXEL;

ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; MALE; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032901680     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)